Search

Displaying results 4851 - 4860 of 8974 in total
  1. Drug

    Phenmetrazine

    go.drugbank.com/drugs/DB00830
    ApprovedIllicit

    Its actions and mechanisms are similar to dextroamphetamine.

  2. Drug

    PSN357

    go.drugbank.com/drugs/DB05044
    Experimental

    PSN357 is a glycogen phosphorylase inhibitor (GPI), which is designed to rapidly lower blood glucose levels by preventing glycogen breakdown to glucose in the liver.

  3. Drug

    inBreath airway transplant system

    go.drugbank.com/drugs/DB18692
    Experimental

    inBreath airway transplant system composes of a scaffold seeded with autologous bone marrow cells and incubated in the bioreactor for two days prior to implant.

  4. Drug

    Voacamine

    go.drugbank.com/drugs/DB04877
    Experimental

    It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.

  5. Drug

    Regramostim

    go.drugbank.com/drugs/DB05386
    Investigational

    Regramostim (GM-CSF) is a differentially glycosylated factor produced mainly by activated T cells and macrophages. … Endothelial cells and fibroblasts can also produce GM-CSF after exposure to TNF-α, IL-1, IL-2 and IFN-γ. GM-CSF is found associated with extracellular matrix and in membrane-bound formats too.

  6. Drug

    Fluciclatide

    go.drugbank.com/drugs/DB14842
    Investigational

    Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis. … The conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms

  7. Drug

    COVID19 s-vax loaded autologous dendritic cell vaccine

    go.drugbank.com/drugs/DB15814
    Experimental

    , and are able to present antigens through costimulatory signals required for activation of CD4+ and CD8+ T-cells. … Dendritic Cells (DCs) are showing potential as natural adjuvants for vaccines due to their ability to both prime and boost cell responses; they are considered the most powerful antigen-presenting cells

  8. Drug

    NKG2D-ACE2 CAR-NK Cell

    go.drugbank.com/drugs/DB15727
    Investigational

    First used with autologous human T cells (CAR-T) as cancer immunotherapies, these receptors are now being engineered onto natural killer (NK) cells due to lower potential for graft-versus-host disease … The ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells.

  9. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.

  10. Drug

    Vanillyl butyl ether

    go.drugbank.com/drugs/DB11299
    Approved

    It is added to food products as a flavoring agent. … It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.